Research

Leads: Joris de Groot, Ulrich Schotten

WP1 collects and analyzes atrial tissue from patients undergoing heart surgery to study how comorbidities and sex influence the structural and electrical properties of the atria. Using high-resolution mapping, histology, and molecular assays, WP1 explores how atrial cardiomyopathy (AtCM) develops and leads to atrial fibrillation (AF). It provides mechanistic insights and clinical parameters essential for all other WPs.

Lead: Monika Stoll

WP2 integrates bulk and single-nucleus RNA sequencing to identify gene expression profiles associated with AtCM, AF, sex, and comorbidities. It links molecular findings to tissue characteristics and electrophysiological traits, providing mechanistic targets and cell-type-specific signatures. These findings guide validation studies and improve patient stratification.

Leads: Vincent Christoffels, Daniël Pijnappels

WP3 functionally tests candidate genes and pathways from WP2 using conditionally immortalized human atrial myocytes and transgenic mice. It explores how specific molecular alterations affect AF susceptibility and response to therapy, aiming to identify potential targets for future AF treatments.

Leads: Jordi Heijman, Rik Vullings

WP4 builds patient-level and mechanistic models to simulate AF progression and therapy effects based on individual AtCM mechanisms. Using continuous rhythm data and AI, it identifies clinical and digital biomarkers to predict progression and personalize care. These tools will support decision-making and future trial design.

Lead: Michiel Rienstra

WP5 conducts a nationwide randomized trial testing early AF ablation vs. standard rate control in asymptomatic patients with early AtCM. The goal is to determine whether early rhythm control prevents disease progression and cardiovascular complications. The trial integrates digital tools like Fibricheck for remote rhythm monitoring.

Leads: Ron Pisters, Martin Hemels, Robert Tieleman

WP6 uses data from the DUTCH-WAIST and VERAPAF trials to investigate whether weight loss or type of rate control therapy can halt or slow AtCM progression. It combines biomarker, imaging, and ECG-based endpoints to assess structural changes over time.

Lead: Geert-Jan Geersing with YourRhythmics BV

This component ensures that EmbRACE findings translate into clinical care through new care pathways, risk models, and eHealth strategies. Working with professional societies, patient organizations, and SMEs like YourRhythmics BV and Fibricheck, the consortium promotes implementation, public awareness, and future funding efforts.

Coordinator: Fleur Tjong and Isabelle van Gelder

The Young Talent Programme supports early-career researchers through mentorship, training, and participation in EmbRACE’s scientific and clinical activities. It ensures sustainable expertise in AF research and fosters the next generation of translational leaders in cardiovascular science.